XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss $ (16,386,000) $ (15,056,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property and equipment 30,000 29,000
Redeemable warrants valuation adjustment (35,000)
Abandonment of patent and trademark rights 14,000
Amortization of patent, trademark rights 150,000 57,000
Non-cash lease expense 151,000 (717,000)
Gain on sale of income tax operating losses (900,000) (749,000)
Equity-based compensation 182,000 792,000
Loss on sale of investments 201,000 1,768,000
Change in assets and liabilities:    
Other receivables (9,000)
Funds receivable from New Jersey net operating loss 1,676,000 1,641,000
Prepaid expenses and other current assets and other non-current assets 192,000 (500,000)
Lease liability (136,000) 717,000
Other assets (73,000)
Accounts payable 2,411,000 758,000
Accrued expenses 915,000 1,329,000
Net cash used in operating activities (11,509,000) (10,039,000)
Cash flows from investing activities:    
Proceeds from sale of marketable investments 924,000 9,082,000
Purchase of marketable investments (1,155,000) (1,661,000)
(Purchase of) Proceeds from sale of property and equipment (10,000) 300,000
Purchase of patent and trademark rights (377,000) (96,000)
Net cash (used in) provided by investing activities (618,000) 7,625,000
Cash flows from financing activities:    
Proceeds from sale of stock, net of issuance costs 338,000 80,000
Net cash provided by financing activities 338,000 80,000
Net decrease in cash and cash equivalents (11,789,000) (2,334,000)
Cash and cash equivalents at beginning of period 27,053,000 32,093,000
Cash and cash equivalents at end of period 15,264,000 29,759,000
Supplemental disclosures of non-cash investing and financing cash flow information:    
Operating lease liability arising from obtaining right of use asset 49,000 717,000
Unrealized loss on marketable investments (71,000) (1,170,000)
Conversion of Series B preferred $ 6,000 $ 2,000